| ¿µ¹® | multiple myeloma | ÇÑ±Û | ´Ù¹ß°ñ¼öÁ¾ |
|---|---|---|---|
| ¼³¸í | ´Ù¹ß¼º ¿ø¹ß¼º°ñÁ¾¾ç. ¸Ó¸®»À-°¥ºñ»À-º¹Àå»À-ôÃß»À-°ñ¹Ý µî¿¡ Àß ³ªÅ¸³ª°í, ¹°··¹°··ÇÑ Á¾±«¸¦ Çü¼ºÇϸç, »ÀÀÇ Èí¼ö°¡ ÀϾ°í, 40~60¼¼ ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù. °ñ¼öÁ¾ Á¾¾ç¼¼Æ÷´Â ÇüÁú¼¼Æ÷¿¡¼ À¯·¡ÇÑ °ÍÀÌ¾î¼ ÇüÁú¼¼Æ÷Á¾À̶ó°íµµ ÇÑ´Ù. °ú°Å¿¡´Â ÇüÁú¼¼Æ÷¼º°ñ¼öÁ¾ À̿ܿ¡´Â ´Ù¸¥ °ñ¼öÁ¶Ç÷¿ä¼Ò¿¡¼ »ý±â´Â °ñ¼öÁ¾À̶ó°í »ý°¢ÇßÁö¸¸ ÇöÀç´Â ºÎÁ¤µÇ°í ÀÖ´Ù. ÇüÁú¼¼Æ÷´Â ¿ø·¡ ¸é¿ª±Û·ÎºÒ¸°À» »ý»êÇÏ´Â ¼¼Æ÷À̸ç, ±×°ÍÀÌ Á¾¾çÈÇÑ ´Ù¹ß °ñ¼öÁ¾ ȯÀÚ¿¡¼µµ ´ëºÎºÐ Ç÷û ¼Ó¿¡ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ Áõ°¡µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù. Áõ°¡ÇÑ ±Û·ÎºÒ¸°Àº IgG³ª IgAÀÎ °æ¿ì°¡ ¸¹Áö¸¸ ´Ù¸¥ Çüµµ ÀÖ´Ù. °ñ¼öÁ¾ ȯÀÚ ¾à 50%´Â ¿ÀÁÜ¿¡¼ º¥½ºÁÔ½º´Ü¹éÁúÀÌ °ËÃâµÇ´Âµ¥, ÀÌ ´Ü¹éÁúÀÇ ÃàÀû¿¡ ÀÇÇØ ¿ä¼¼°üÀÌ ÆÄ±«µÇ°í, ÄáÆÏ°æÈ°¡ ÀϾÙ. °ñ¼öÁ¾ ȯÀÚ¿¡¼´Â Ç÷û´Ü¹é ÀÌ»óÀ¸·Î °¡²û ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ³ªÅ¸³´Ù. »À X¼± ¼Ò°ßÀ¸·Î¼´Â µµ·Á³½ º´ÅÍ, °ñÀ¶ÇØ»ó, º´Àû°ñÀýÀÌ °üÂûµÈ´Ù. |
||
| ¿µ¹® | white blood cell(WBC), leukocyte | ÇÑ±Û | ¹éÇ÷±¸ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, ȤÀº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀÎ Çö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù. |
||
| ¿µ¹® | mast cell | ÇÑ±Û | ºñ¸¸ ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | µ¿¹°ÀÇ °áÇÕ Á¶Á÷ °¡¿îµ¥ ³Î¸® ºÐÆ÷ÇÏ´Â ¼¼Æ÷. °áÇÕÁ¶Á÷°ú Á¡¸·Á¶Á÷ ³»¿¡ Àִ ȣ¿°±â¼º »ö¼Ò·Î ÀÌ¿°»ö¼º(metachromasia)À» ³ªÅ¸³»´Â °ú¸³À» °¡Áø ¹æÃßÇüÀÇ ¼¼Æ÷¿¡ ÀÛÀº µÕ±Ù ÇÙÀ» °¡Áø´Ù. ºñ¸¸¼¼Æ÷ÀÇ Ç¥¸é¿¡´Â IgE¿¡ ´ëÇÑ ¼ö¿ëü°¡ Á¸ÀçÇϸç, ¼ö¿ëü¿¡ °áÇÕÇÑ IgE ºÐÀڵ鳢¸® ´Ù°¡ÀÇ Ç׿ø¿¡ ÀÇÇØ ¼·Î ¿¬°áµÇ¸é ºñ¸¸¼¼Æ÷ °ú¸³Å»Ãâ ¹ÝÀÀÀÌ ÀϾ, È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ, ÇìÆÄ¸° µîÀÇ ÈÇÐÀü´Þ ¹°ÁúÀÌ ¹æÃâµÇ¾î, Áï½ÃÇü ¾Ë·¹¸£±â ¹ÝÀÀ µîÀÇ Áõ»óÀ» ÀÏÀ¸Å²´Ù. ÇǺÎ, À帷, Ç÷°ü ÁÖÀ§, Á¡¸· ÁÖº¯¿¡ ÀÖ´Ù. |
||
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
|---|---|
| B-J protein | Bence-Jones Protein ÀÇÀÇ; Multiple Myeloma |
| MM | Multiple Myeloma |
| MM | macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle... |
| PC-BMP | phosphorylcholine-m-binding myeloma protein |
| HMCL | human myeloma cell line |
|---|---|
| M.M. | Multiple Myeloma |
| MM | Myeloma |
| SMM | Smoldering multiple myeloma |
| ES cell | embryonic stem cell |
| myeloma cell | <haematology, oncology> Neoplastic plasma cell. The proliferating plasma cells often replace all the others within the marrow, leading to immune deficiency and frequently there is destruction of the bone cortex. Because they are monoclonal in origin they secrete a monoclonal immunoglobulin. Bence Jones proteins are monoclonal immunoglobulin light chains overproduced by myeloma cells and excreted in the urine. Myeloma cell lines are used for producing hybridomas in raising monoclonal antibodies. (18 Nov 1997) |
|---|
| giant cell myeloma | A bone tumour composed of cellular spindle-cell stroma containing scattered multinucleated giant cells resembling osteoclasts. The tumours range from benign to frankly malignant lesions. The tumour occurs most frequently in an end of a long tubular bone in young adults. (12 Dec 1998) |
|---|---|
| plasma cell myeloma | Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma. (05 Mar 2000) |
| amyloidosis of multiple myeloma | Foci of amyloidosis in mesenchymal tissues of some persons with multiple myeloma; no direct relation between amyloid and Bence Jones protein is conclusively known. (05 Mar 2000) |
| cancer, multiple myeloma | A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy. (12 Dec 1998) |
| cancer, myeloma | A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (too much calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly. (12 Dec 1998) |
| multiple myeloma | <oncology, tumour> See myeloma cell. (18 Nov 1997) |
| myeloma | <oncology, tumour> A malignant tumour composed of plasma cells of the type normally found in the bone marrow. (18 Nov 1997) |
| myeloma protein | <haematology, oncology> The immunoglobulins and Bence Jones proteins secreted by myeloma cells. (18 Nov 1997) |
| endothelial myeloma | A malignant primary bone tumour that arises most commonly in the first three decades of life. It is highly malignant (prone to spread) and often requires treatment with some combination of radiation therapy and chemotherapy. (27 Sep 1997) |
| L-chain myeloma | bence Jones myeloma |
| T-cell-rich, B-cell lymphoma | <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component. See: adult T-cell lymphoma. (05 Mar 2000) |
| absorption cell | A small glass chamber with parallel sides, in which absorption spectra of solutions can be obtained. (05 Mar 2000) |
| acid cell | One of the cell's of the gastric glands; it lies upon the basement membrane, covered by the chief cell's, and secretes hydrochloric acid that reaches the lumen of the gland through fine intracellular and intercellular canals (canaliculi). Synonym: acid cell, oxyntic cell. (05 Mar 2000) |
| acidophil cell | A cell whose cytoplasm or its granules stain with acid dyes. (05 Mar 2000) |
| acinar cell | Any secreting cell lining an acinus, especially applied to the cell's of the pancreas that furnish pancreatic juice and enzymes to distinguish them from the cell's of ducts and the islets of Langerhans. Synonym: acinous cell. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|